论文部分内容阅读
目的评价比阿培南治疗急性白血病粒细胞减少期合并感染的临床疗效及安全性。方法采用随机对照试验方法,选用亚胺培南为对照组,两组分别40例。结果比阿培南组有效率和不良反应发生率分别为90%、7.5%,亚胺培南组有效率和不良反应发生率分别为87.5%、5%,两组之间差异均无统计学意义。结论应用比阿培南治疗急性白血病粒细胞减少期合并感染患者,疗效确切,不良反应少,与亚胺培南相似,可以在急性白血病粒细胞减少期合并感染的患者中使用。
Objective To evaluate the clinical efficacy and safety of biapenem in the treatment of acute leukemia with granulocytopenic infection. Methods Randomized controlled trials were used, imipenem as the control group, 40 cases in each group. Results The incidence of side effects and adverse reactions in biapenem group were 90% and 7.5%, respectively, and the rates of effective and adverse reactions in imipenem group were 87.5% and 5% respectively, with no statistical difference significance. Conclusion Biapenem in the treatment of patients with acute leukemia with agranulocytosis complicated with infection, the exact effect, fewer adverse reactions, similar to imipenem, can be used in patients with acute leukemia associated with agranulocytosis.